OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Forecast, Price & News $45.74 0.00 (0.00%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$45.74▼$45.7450-Day Range$41.20▼$47.2552-Week Range$25.12▼$47.25Volume214 shsAverage Volume1,448 shsMarket CapitalizationN/AP/E Ratio14.78Dividend Yield0.70%Price TargetN/A ProfileProfileChartCompetitorsDividendHeadlinesShort InterestProfileChartCompetitorsDividendHeadlinesShort Interest About Hikma Pharmaceuticals (OTCMKTS:HKMPY) StockHikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.Read More Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Stock News HeadlinesMay 5, 2023 | marketwatch.comHikma Pharmaceuticals rises Friday, still underperforms marketMay 3, 2023 | marketwatch.comHikma Pharmaceuticals rises Wednesday, outperforms marketMay 28, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 19, 2023 | finance.yahoo.comHikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 7, 2023 | uk.investing.comHikma Pharmaceuticals PLC (HIK)January 31, 2023 | marketwatch.comHikma Pharmaceuticals rises Tuesday, outperforms marketJanuary 24, 2023 | marketwatch.comHikma Pharmaceuticals falls Tuesday, underperforms marketDecember 27, 2022 | msn.comJunshi inks licensing deal with Hikma for toripalimab; FDA filing still under reviewMay 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!December 26, 2022 | financialpost.comJunshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa RegionDecember 15, 2022 | marketwatch.comHikma Pharmaceuticals rises Thursday, outperforms marketOctober 9, 2022 | finance.yahoo.comHikma Pharmaceuticals PLC (HKMPY)September 28, 2022 | reuters.comHKMPY.PK - | Stock Price & Latest News | ReutersSeptember 25, 2022 | uk.finance.yahoo.comHikma Pharmaceuticals PLC (H5P.F)August 30, 2022 | finance.yahoo.comHikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the USJuly 17, 2022 | benzinga.comHikma Pharmaceuticals (OTC:HKMPY), Analyst Ratings, Price Targets, PredictionsMay 24, 2022 | news.yahoo.comDrugmaker Hikma's CEO Olafsson to step downMay 14, 2022 | finance.yahoo.comInvestors in Hikma Pharmaceuticals (LON:HIK) have unfortunately lost 26% over the last yearApril 21, 2022 | finance.yahoo.comHikma completes acquisition of CustopharmApril 20, 2022 | seekingalpha.comHikma gets preliminary approval from FTC to acquire CustopharmApril 20, 2022 | finance.yahoo.comHikma confirms FTC preliminary approval for CustopharmApril 19, 2022 | finance.yahoo.comU.S. FTC approves Hikma deal for Custopharm with conditionsFebruary 27, 2022 | finance.yahoo.comAnalysts Have Made A Financial Statement On Hikma Pharmaceuticals PLC's (LON:HIK) Yearly ReportNovember 9, 2021 | finance.yahoo.comThose who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 62%October 22, 2021 | finance.yahoo.comHikma donates 50,000 doses of injectable naloxone to help expand non-profit access to lifesaving treatment for reversing opioid overdosesSeptember 27, 2021 | finance.yahoo.comHikma Bolsters Injectable Portfolio With $375M Custopharm AcquisitionSeptember 27, 2021 | finance.yahoo.comHikma strengthens US Injectables business through acquisition of CustopharmSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Company Calendar Ex-Dividend for 5/15 Dividend3/23/2023Dividend Payable5/15/2023Today5/28/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HKMPY CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees8,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio14.78 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesSaid Samih Taleb DarwazahExecutive Chairman & Chief Executive OfficerKhalid Walid Hosni NabilsiChief Financial OfficerMazen Samih Taleb DarwazahExecutive Vice Chairman & President-MENA RegionMajda LabadiExecutive VP-Organizational DevelopmentRiad MishlawiPresident-Injectables DivisionKey Competitors1933 IndustriesOTCMKTS:TGIFF4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFAcreageOTCMKTS:ACRHFView All Competitors HKMPY Stock - Frequently Asked Questions How have HKMPY shares performed in 2023? Hikma Pharmaceuticals' stock was trading at $36.95 at the beginning of the year. Since then, HKMPY stock has increased by 23.8% and is now trading at $45.74. View the best growth stocks for 2023 here. Are investors shorting Hikma Pharmaceuticals? Hikma Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 100 shares, a decrease of 98.0% from the April 30th total of 5,000 shares. Based on an average trading volume of 2,300 shares, the days-to-cover ratio is presently 0.0 days. View Hikma Pharmaceuticals' Short Interest. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Friday, March 17th. Investors of record on Friday, March 24th will be paid a dividend of $0.72 per share on Monday, May 15th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, March 23rd. This is a positive change from the stock's previous dividend of $0.36. Read our dividend analysis for HKMPY. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for HKMPY. What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY." How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Hikma Pharmaceuticals' stock price today? One share of HKMPY stock can currently be purchased for approximately $45.74. How many employees does Hikma Pharmaceuticals have? The company employs 8,700 workers across the globe. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at 442073992760. This page (OTCMKTS:HKMPY) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.